Roflumilast reduces myocardial ischemia reperfusion injury in vivo and in vitro by activating the AMPK signaling pathway

Liao,Bo; Han,Zhongyuan

doi:10.3892/etm.2023.12001

Roflumilast reduces myocardial ischemia reperfusion injury in vivo and in vitro by activating the AMPK signaling pathway

Authors:
- Bo Liao
- Zhongyuan Han
View Affiliations

Affiliations: Department of Cardiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, Department of Cardiovascular Medicine, The Second People's Hospital of Nantong, Nantong, Jiangsu 226002, P.R. China
Published online on: May 9, 2023 https://doi.org/10.3892/etm.2023.12001
Article Number: 302
Copyright: © Liao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Myocardial tissue cell damage induced by myocardial ischemia/reperfusion (MI/R) notably elevates the mortality rate, increases the complications of patients with myocardial infarction and decreases reperfusion benefit in patients suffering from acute myocardial infarction. Roflumilast protect against cardiotoxicity. Therefore, the present study aimed to investigate the effect of roflumilast on MI/R injury and the underlying mechanisms. To simulate MI/R in vivo and in vitro, the rat model of MI/R was established and H9C2 cells were subjected to hypoxia/reoxygenation (H/R) induction, respectively. The myocardial infarction areas were observed by 2,3,5‑triphenyltetrazolium chloride staining. The myocardial enzyme levels in serum and levels of inflammatory cytokines and oxidative stress markers in cardiac tissue were assessed by corresponding assay kits. The cardiac damage was observed by hematoxylin and eosin staining. The mitochondrial membrane potential in cardiac tissue and H9C2 cells was detected using the JC‑1 staining kit. The viability and apoptosis of H9C2 cells were detected by Cell Counting Kit‑8 and TUNEL assay, respectively. The levels of inflammatory cytokines, oxidative stress markers and ATP in H/R‑induced H9C2 cells were analyzed by corresponding assay kits. Western blotting was used for the estimation of AMP‑activated protein kinase (AMPK) signaling pathway‑, apoptosis‑ and mitochondrial regulation‑associated protein levels. The mPTP opening was detected using a calcein‑loading/cobalt chloride‑quenching system. The results indicated that roflumilast decreased MI/R‑induced myocardial infarction by alleviating myocardial injury and mitochondrial damage through the activation of the AMPK signaling pathway. In addition, roflumilast mitigated viability damage, alleviated oxidative stress, attenuated the inflammatory response and decreased mitochondrial damage in H/R‑induced H9C2 cells by activating the AMPK signaling pathway. However, compound C, an inhibitor of the AMPK signaling pathway, reversed the effect of roflumilast on H/R‑induced H9C2 cells. In conclusion, roflumilast alleviated myocardial infarction in MI/R rats and attenuated H/R‑induced oxidative stress, inflammatory response and mitochondrial damage in H9C2 cells by activating the AMPK signaling pathway.

View Figures

View References

1	Weinberger T and Schulz C: Myocardial infarction: A critical role of macrophages in cardiac remodeling. Front Physiol. 6(107)2015.PubMed/NCBI View Article : Google Scholar
2	Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, Chavey WE II, Fesmire FM, Hochman JS, Levin TN, et al: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: A report of the American college of cardiology/american heart association task force on practice guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American college of emergency physicians, the society for cardiovascular angiography and interventions, and the society of Thoracic surgeons endorsed by the American association of cardiovascular and pulmonary rehabilitation and the society for academic emergency medicine. J Am Coll Cardiol. 50:e1–e157. 2007.PubMed/NCBI View Article : Google Scholar
3	Hu S, Gao R, Liu L, Zhu M, Wang W, Wang Y, Wu Z, Li H, Gu D, Yang Y, et al: Summary of the 2018 report on cardiovascular diseases in China. Chin Circulat J. 34:209–220. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
4	Liu S, Li Y, Zeng X, Wang H, Yin P, Wang L, Liu Y, Liu J, Qi J, Ran S, et al: Burden of cardiovascular diseases in China, 1990-2016: Findings from the 2016 global burden of disease study. JAMA Cardiol. 4:342–352. 2019.PubMed/NCBI View Article : Google Scholar
5	Wu Y, Li S, Patel A, Li X, Du X, Wu T, Zhao Y, Feng L, Billot L, Peterson ED, et al: Effect of a quality of care improvement initiative in patients with acute coronary syndrome in resource-constrained hospitals in China: A randomized clinical trial. JAMA Cardiol. 4:418–427. 2019.PubMed/NCBI View Article : Google Scholar
6	Farah A and Barbagelata A: Unmet goals in the treatment of acute myocardial infarction: Review. F1000Res 6: Faculty Rev-1243, 2017.
7	Hausenloy DJ and Yellon DM: Myocardial ischemia-reperfusion injury: A neglected therapeutic target. J Clin Invest. 123:92–100. 2013.PubMed/NCBI View Article : Google Scholar
8	Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med. 357:1121–1135. 2007.PubMed/NCBI View Article : Google Scholar
9	Janjua S, Fortescue R and Poole P: Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 5(CD002309)2020.PubMed/NCBI View Article : Google Scholar
10	Xu B, Xu J, Cai N, Li M, Liu L, Qin Y, Li X and Wang H: Roflumilast prevents ischemic stroke-induced neuronal damage by restricting GSK3β-mediated oxidative stress and IRE1α/TRAF2/JNK pathway. Free Radic Biol Med. 163:281–296. 2021.PubMed/NCBI View Article : Google Scholar
11	Xu X, Liao L, Hu B, Jiang H and Tan M: Roflumilast, a phosphodiesterases-4 (PDE4) inhibitor, alleviates sepsis-induced acute kidney injury. Med Sci Monit. 26(e921319)2020.PubMed/NCBI View Article : Google Scholar
12	Kwak HJ, Park KM, Choi HE, Chung KS, Lim HJ and Park HY: PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways. Cell Signal. 20:803–814. 2008.PubMed/NCBI View Article : Google Scholar
13	Ansari MN, Ganaie MA, Rehman NU, Alharthy KM, Khan TH, Imam F, Ansari MA, Al-Harbi NO, Jan BL, Sheikh IA and Hamad AM: Protective role of Roflumilast against cadmium-induced cardiotoxicity through inhibition of oxidative stress and NF-κB signaling in rats. Saudi Pharm J. 27:673–681. 2019.PubMed/NCBI View Article : Google Scholar
14	Zhang S, Wu P, Liu J, Du Y and Yang Z: Roflumilast attenuates doxorubicin-induced cardiotoxicity by targeting inflammation and cellular senescence in cardiomyocytes mediated by SIRT1. Drug Des Devel Ther. 15:87–97. 2021.PubMed/NCBI View Article : Google Scholar
15	Perrelli MG, Pagliaro P and Penna C: Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species. World J Cardiol. 3:186–200. 2011.PubMed/NCBI View Article : Google Scholar
16	Penna C, Perrelli MG and Pagliaro P: Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: Therapeutic implications. Antioxid Redox Signal. 18:556–599. 2013.PubMed/NCBI View Article : Google Scholar
17	Kyung SY, Kim YJ, Son ES, Jeong SH and Park JW: The phosphodiesterase 4 inhibitor roflumilast protects against cigarette smoke extract-induced mitophagy-dependent cell death in epithelial cells. Tuberc Respir Dis (Seoul). 81:138–147. 2018.PubMed/NCBI View Article : Google Scholar
18	Zhou H, Zhang Y, Hu S, Shi C, Zhu P, Ma Q, Jin Q, Cao F, Tian F and Chen Y: Melatonin protects cardiac microvasculature against ischemia/reperfusion injury via suppression of mitochondrial fission-VDAC1-HK2-mPTP-mitophagy axis. J Pineal Res. 63(e12413)2017.PubMed/NCBI View Article : Google Scholar
19	Tian L, Cao W, Yue R, Yuan Y, Guo X, Qin D, Xing J and Wang X: Pretreatment with Tilianin improves mitochondrial energy metabolism and oxidative stress in rats with myocardial ischemia/reperfusion injury via AMPK/SIRT1/PGC-1 alpha signaling pathway. J Pharmacol Sci. 139:352–360. 2019.PubMed/NCBI View Article : Google Scholar
20	Tikoo K, Lodea S, Karpe PA and Kumar S: Calorie restriction mimicking effects of roflumilast prevents diabetic nephropathy. Biochem Biophys Res Commun. 450:1581–1586. 2014.PubMed/NCBI View Article : Google Scholar
21	Qian L, Shi J, Zhang C, Lu J, Lu X, Wu K, Yang C, Yan D, Zhang C, You Q, et al: Downregulation of RACK1 is associated with cardiomyocyte apoptosis after myocardial ischemia/reperfusion injury in adult rats. In Vitro Cell Dev Biol Anim. 52:305–313. 2016.PubMed/NCBI View Article : Google Scholar
22	Tahrir FG, Langford D, Amini S, Ahooyi TM and Khalili K: Mitochondrial quality control in cardiac cells: Mechanisms and role in cardiac cell injury and disease. J Cell Physiol. 234:8122–8133. 2019.PubMed/NCBI View Article : Google Scholar
23	Seidlmayer LK, Juettner VV, Kettlewell S, Pavlov EV, Blatter LA and Dedkova EN: Distinct mPTP activation mechanisms in ischaemia-reperfusion: Contributions of Ca2+, ROS, pH, and inorganic polyphosphate. Cardiovasc Res. 106:237–248. 2015.PubMed/NCBI View Article : Google Scholar
24	Ong SB and Hausenloy DJ: Mitochondrial dynamics as a therapeutic target for treating cardiac diseases. Handb Exp Pharmacol. 240:251–279. 2017.PubMed/NCBI View Article : Google Scholar
25	Vásquez-Trincado C, García-Carvajal I, Pennanen C, Parra V, Hill JA, Rothermel BA and Lavandero S: Mitochondrial dynamics, mitophagy and cardiovascular disease. J Physiol. 594:509–525. 2016.PubMed/NCBI View Article : Google Scholar
26	Shoshan-Barmatz V and De S: Mitochondrial VDAC, the Na(+)/Ca(2+) exchanger, and the Ca(2+) uniporter in Ca(2+) dynamics and signaling. Adv Exp Med Biol. 981:323–347. 2017.PubMed/NCBI View Article : Google Scholar
27	Li Y and Liu X: Novel insights into the role of mitochondrial fusion and fission in cardiomyocyte apoptosis induced by ischemia/reperfusion. J Cell Physiol. 233:5589–5597. 2018.PubMed/NCBI View Article : Google Scholar
28	Maneechote C, Palee S, Chattipakorn SC and Chattipakorn N: Roles of mitochondrial dynamics modulators in cardiac ischaemia/reperfusion injury. J Cell Mol Med. 21:2643–2653. 2017.PubMed/NCBI View Article : Google Scholar
29	Leucker TM, Bienengraeber M, Muravyeva M, Baotic I, Weihrauch D, Brzezinska AK, Warltier DC, Kersten JR and Pratt PF Jr: Endothelial-cardiomyocyte crosstalk enhances pharmacological cardioprotection. J Mol Cell Cardiol. 51:803–811. 2011.PubMed/NCBI View Article : Google Scholar
30	Hardie DG: AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis. Curr Opin Cell Biol. 33:1–7. 2015.PubMed/NCBI View Article : Google Scholar
31	Zhao B, Qiang L, Joseph J, Kalyanaraman B, Viollet B and He YY: Mitochondrial dysfunction activates the AMPK signaling and autophagy to promote cell survival. Genes Dis. 3:82–87. 2016.PubMed/NCBI View Article : Google Scholar
32	Hwang JT, Kwon DY, Park OJ and Kim MS: Resveratrol protects ROS-induced cell death by activating AMPK in H9c2 cardiac muscle cells. Genes Nutr. 2:323–326. 2008.PubMed/NCBI View Article : Google Scholar
33	Sasaki H, Asanuma H, Fujita M, Takahama H, Wakeno M, Ito S, Ogai A, Asakura M, Kim J, Minamino T, et al: Metformin prevents progression of heart failure in dogs: Role of AMP-activated protein kinase. Circulation. 119:2568–2577. 2009.PubMed/NCBI View Article : Google Scholar
34	Wang XF, Zhang JY, Li L and Zhao XY: Beneficial effects of metformin on primary cardiomyocytes via activation of adenosine monophosphate-activated protein kinase. Chin Med J (Engl). 124:1876–1884. 2011.PubMed/NCBI
35	Yeh CH, Chen TP, Wang YC, Lin YM and Fang SW: AMP-activated protein kinase activation during cardioplegia-induced hypoxia/reoxygenation injury attenuates cardiomyocytic apoptosis via reduction of endoplasmic reticulum stress. Mediators Inflamm. 2010(130636)2010.PubMed/NCBI View Article : Google Scholar
36	Chen MB, Wu XY, Gu JH, Guo QT, Shen WX and Lu PH: Activation of AMP-activated protein kinase contributes to doxorubicin-induced cell death and apoptosis in cultured myocardial H9c2 cells. Cell Biochem Biophys. 60:311–322. 2011.PubMed/NCBI View Article : Google Scholar
37	Chin JT, Troke JJ, Kimura N, Itoh S, Wang X, Palmer OP, Robbins RC and Fischbein MP: A novel cardioprotective agent in cardiac transplantation: Metformin activation of AMP-activated protein kinase decreases acute ischemia-reperfusion injury and chronic rejection. Yale J Biol Med. 84:423–432. 2011.PubMed/NCBI
38	Kim AS, Miller EJ, Wright TM, Li J, Qi D, Atsina K, Zaha V, Sakamoto K and Young LH: A small molecule AMPK activator protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol. 51:24–32. 2011.PubMed/NCBI View Article : Google Scholar
39	McGaffin KR, Witham WG, Yester KA, Romano LC, O'Doherty RM, McTiernan CF and O'Donnell CP: Cardiac-specific leptin receptor deletion exacerbates ischaemic heart failure in mice. Cardiovasc Res. 89:60–71. 2011.PubMed/NCBI View Article : Google Scholar
40	Kosutova P, Mikolka P, Kolomaznik M, Balentova S, Adamkov M, Calkovska A and Mokra D: Reduction of lung inflammation, oxidative stress and apoptosis by the PDE4 inhibitor roflumilast in experimental model of acute lung injury. Physiol Res. 67:S645–S654. 2018.PubMed/NCBI View Article : Google Scholar
41	Kahles F, Mllmann J, Bck C, Liberman A and Lehrke M: The PDE-4 Inhibitor Roflumilast reduces weight gain, enhances insulin sensitivity and prevents hepatic steatosis in mice by increasing mitochondrogenesis. Diabetologie Und Stoffwechsel. 9:1993–2003. 2014.
42	Rezvanfar MA, Rezvanfar MA, Ranjbar A, Baeeri M, Mohammadirad A and Abdollahi M: Biochemical evidence on positive effects of rolipram a phosphodiesterase-4 inhibitor in malathion-induced toxic stress in rat blood and brain mitochondria. Pesticide Biochemistry & Physiology. 98:135–143. 2010.
43	Xu W, Zhang J and Xiao J: Roflumilast suppresses adipogenic differentiation via AMPK mediated pathway. Front Endocrinol (Lausanne). 12(662451)2021.PubMed/NCBI View Article : Google Scholar